Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development

Author： Wangari-Talbot Janet   Goydos James   Chen Suzie  

Publisher： MDPI

E-ISSN： 1424-8247|3|9|2821-2837

ISSN： 1424-8247

Source： Pharmaceuticals, Vol.3, Iss.9, 2010-08, pp. : 2821-2837

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Melanoma remains one of the cancers for which a decline in morbidity has not been achieved with current scientific and medical advances. Mono-therapies targeting melanoma have been largely ineffective, increasing the need for identification of new drugable targets. Multiple tumor suppressors and oncogenes that impart genetic predisposition to melanoma have been identified and are being studied in an attempt to provide insight on the development of anti-melanoma therapies. Metabotropic Glutamate Receptor I (GRM1) has recently been implicated as a novel oncogene involved in melanomagenesis. GRM1 (mGlu1, protein) belongs to the G protein coupled receptor (GPCR) super family and is normally functional in the central nervous system. Our group showed in a transgenic mouse model system that ectopic expression of Grm1 in melanocytes is sufficient to induce spontaneous melanoma development in vivo. GPCRs are some of the most important therapeutic drug targets discovered to date and they make up a significant proportion of existing therapies. This super family of transmembrane receptors has wide spread expression and interacts with a diverse array of ligands. Diverse physiological responses can be induced by stimulator(s) or suppressor(s) of GPCRs, which contributes to their attractiveness in existing and emerging therapies. GPCR targeting therapies are employed against a variety of human disorders including those of the central nervous system, cardiovascular, metabolic, urogenital and respiratory systems. In the current review, we will discuss how the identification of the oncogenic properties of GRM1 opens up new strategies for the design of potential novel therapies for the treatment of melanoma.

Related content

Interactions between Two Different G Protein-Coupled Receptors in Reproductive Hormone-Producing Cells: The Role of PACAP and Its Receptor PAC1R

By Kanasaki Haruhiko   Oride Aki   Hara Tomomi   Mijiddorj Tselmeg   Sukhbaatar Unurjargal   Kyo Satoru  

International Journal of Molecular Sciences, Vol. 17, Iss. 10, 2016-09 ,pp. : 1635-1635 (1)

MDPI

Access to resources Recommend Favorite

Molecular Actions of Ovarian Cancer G Protein-Coupled Receptor 1 Caused by Extracellular Acidification in Bone

By Yuan Feng-Lai   Zhao Ming-Dong   Jiang Li-Bo   Wang Hui-Ren   Cao Lu   Zhou Xiao-Gang   Li Xi-Lei   Dong Jian  

International Journal of Molecular Sciences, Vol. 15, Iss. 12, 2014-12 ,pp. : 22365-22373 (9)

MDPI

Access to resources Recommend Favorite

G Protein-Coupled Receptor Signaling in Stem Cells and Cancer

By Lynch Jennifer R.   Wang Jenny Yingzi  

International Journal of Molecular Sciences, Vol. 17, Iss. 5, 2016-05 ,pp. : 707-707 (1)

MDPI

Access to resources Recommend Favorite

Acidosis Decreases c-Myc Oncogene Expression in Human Lymphoma Cells: A Role for the Proton-Sensing G Protein-Coupled Receptor TDAG8

By Li Zhigang   Dong Lixue   Dean Eric   Yang Li V.  

International Journal of Molecular Sciences, Vol. 14, Iss. 10, 2013-10 ,pp. : 20236-20255 (20)

MDPI

Access to resources Recommend Favorite

G Protein-Coupled Receptors in Cancer

By Bar-Shavit Rachel   Maoz Myriam   Kancharla Arun   Nag Jeetendra Kumar   Agranovich Daniel   Grisaru-Granovsky Sorina   Uziely Beatrice  

International Journal of Molecular Sciences, Vol. 17, Iss. 8, 2016-08 ,pp. : 1320-1320 (1)

MDPI

Access to resources Recommend Favorite